ArticleInternational journal of nanomedicine2013
The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 69 citations in OpenAlex.
- Advancements in zinc oxide nanofibers for enhanced rehabilitation and injury recovery: mechanisms, applications, and future directions.Journal of biological engineering · 2025Review
- Article
- Biosynthesis of Zinc Oxide-Zerumbone (ZnO-Zer) Nanoflakes Towards Evaluating Its Antibacterial and Reactive Oxygen Species (ROS)-Dependent Cytotoxic Activity.Journal of fluorescence · 2025Article
- Characterization and Cytotoxicity Assessment of Synthesized Palladium (II) Complex-Encapsulated Zinc Oxide Nanoparticles for Cancer Treatment.Cell biochemistry and biophysics · 2024Article
- Functionalized ZnO-Based Nanocomposites for Diverse Biological Applications: Current Trends and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2024Review
- Metal-Based Nanoparticles and Their Relevant Consequences on Cytotoxicity Cascade and Induced Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Review
- Cytotoxicity towards Breast Cancer Cells of Pluronic F-127/Hyaluronic Acid Hydrogel Containing Nitric Oxide Donor and Silica Nanoparticles Loaded with Cisplatin.Pharmaceutics · 2022Article
- Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications.Journal of nanobiotechnology · 2022Review
- Electrically Conductive Hydrogels for Articular Cartilage Tissue Engineering.Gels (Basel, Switzerland) · 2022Review
- The Anti-Proliferative Activity of Coordination Compound-Based ZnO Nanoparticles as a Promising Agent Against Triple Negative Breast Cancer Cells.International journal of nanomedicine · 2021Article
- Metal Oxide Nanoparticles as Biomedical Materials.Biomimetics (Basel, Switzerland) · 2020Review
- Methods for Reducing the Toxicity of Metal and Metal Oxide NPs as Biomedicine.Materials (Basel, Switzerland) · 2020Review
- Effects of Zinc Oxide Nanoparticles in HUVEC: Cyto- and Genotoxicity and Functional Impairment After Long-Term and Repetitive Exposure in vitro.International journal of nanomedicine · 2020Article
- Chemotherapy of Breast Cancer Cells Using Novel pH-Responsive Cellulose-Based Nanocomposites.Advanced pharmaceutical bulletin · 2019Article
- Silk Fibroin-Coated Nanoagents for Acidic Lysosome Targeting by a Functional Preservation Strategy in Cancer Chemotherapy.Theranostics · 2019Article
- Microwave induced synthesis of ZnO nanorods and their efficacy as a drug carrier with profound anticancer and antibacterial properties.Toxicology reports · 2019Article
- ZnO Nanostructures for Drug Delivery and Theranostic Applications.Nanomaterials (Basel, Switzerland) · 2018Review
- The Advancing of Zinc Oxide Nanoparticles for Biomedical Applications.Bioinorganic chemistry and applications · 2018Review
- Doxorubicin-Wrapped Zinc Oxide Nanoclusters for the Therapy of Colorectal Adenocarcinoma.Nanomaterials (Basel, Switzerland) · 2017Article
- Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.Journal of cancer research and clinical oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanomaterials have emerged as ideal multimodal nanomedicine platforms, each one combining different designs and therapeutic approaches in a single system against cancer. The aim of the current study was to explore the synergistic effect and mechanism of a doxorubicin (Dox)-ZnO nanocomplex as a multimodal drug delivery system, integrating Dox chemotherapy and ZnO-mediated photodynamic therapy, in anticancer therapeutics.
methodsDox was loaded onto ZnO nanomaterials, forming complexes with the transition metal Zn to yield the Dox-ZnO nanocomplexes. After culture with SMMC-7721 hepatocarcinoma cells, the cellular uptake was quantitatively detected by flow cytometry and visualized by fluorescence microscopy. The synergistic effects of the different anticancer therapeutic modalities on the proliferation of SMMC-7721 hepatocarcinoma cells were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression of B-cell lymphoma 2 protein (Bcl-2), Bcl-2 associated X protein (Bax), caspase 9, and caspase 3 were examined by Western blot, to elucidate the possible molecular mechanisms involved.
resultsOur observations demonstrated that Dox-ZnO nanocomplexes could act as an efficient drug delivery system for importing Dox into SMMC-7721 cells, enhancing its potential chemotherapy efficiency by increasing the intracellular concentration of Dox. With the addition of ultraviolet (UV) illumination, the ZnO nanomaterials showed excellent photodynamic therapeutic properties, attacking the cancer cells further. Thus the caspase-dependent apoptosis was synergistically induced, resulting in distinct improvement in anticancer activity.
conclusionThe Dox-ZnO nanocomplex presents a promising multimodal agent for comprehensive cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.